Skip to main content
Log in

Successful treatment with anti-tumor necrosis factor (anti-TNF)-alpha of proteinuria in a patient with familial mediterranean fever (FMF) resistant to colchicine: anti-TNF drugs and FMF

  • Letter to the Editor
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Familial mediterranean fever (FMF) is an autoinflammatory disease characterized by recurrent attacks of fever, peritonitis, pleuritis, and genetically by autosomal recessive inheritance. The major renal involvement in FMF is the occurrence of amyloidosis that can be prevented by a daily regimen of colchicine. About 5–10% of cases with familial mediterranean fever may be resistant to colchicine. In literature, there is a controversy about the treatment of FMF patients resistant to colchicine. We describe a case with FMF, proteinuria, and bilateral sacroiliitis, which responded to anti-TNF (tumor necrosis factor)-alpha therapy with infliximab and etanercept.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Nakamura A, Matsuda M, Tazawa K, Shimojima Y, Ikeda S (2007) Successful treatment with infliximab and low-dose methotrexate in a Japanese patient with familial mediterranean fever. Intern Med 46(15):1247–1249

    Article  PubMed  Google Scholar 

  2. El-Shanti HI (2003) Familial mediterranean fever and renal disease. Saudi J Kidney Dis Transpl 14(3):378–385

    PubMed  Google Scholar 

  3. Ben-Chetrit E, Levy M (1998) Familial mediterranean fever. Lancet 351:659–664

    Article  PubMed  CAS  Google Scholar 

  4. Lidar M, Scherrmann JM, Shinar Y, Chetrit A, Niel E, Gershoni-Baruch R, Langevitz P, Livneh A (2004) Colchicine nonresponsiveness in familial mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Arthritis Rheum 33(4):273–282

    Article  CAS  Google Scholar 

  5. Brik R, Shinawi M, Kasinetz L, Gershoni-Baruch R (2001) The musculoskeletal manifestations of familial mediterranean fever in children genetically diagnosed with the disease. Arthritis Rheum 44(6):1416–1419

    Article  PubMed  CAS  Google Scholar 

  6. Incel NA, Saracoglu M, Erdem HR (2003) Seronegative spondiloarthropathy of familial mediterranean fever. Rheum Int 23(1):41–43

    Google Scholar 

  7. Ozen S, Bakkaloglu A, Yilmaz E, Duzova A, Balci B, Topaloglu R, Besbas N (2003) Mutations in the gene for familial mediterranean fever: do they predispose to inflammation. J Rheum 30(9):2014–2018

    PubMed  CAS  Google Scholar 

  8. Metyas S, Arkfeld DG, Forrester DM, Ehresmann GR (2004) Infliximab treatment of familial mediterranean fever and its effect on secondary AA amyloidosis. J Clin Rheum 10(3):134–137

    Article  Google Scholar 

  9. Sakallioglu O, Duzova A, Ozen S (2006) Etanercept in the treatment of arthritis in a patient with familial mediterranean fever. Clin Exp Rheumatol 24:435–437

    PubMed  CAS  Google Scholar 

  10. Ozgocmen S, Ozçakar L, Ardicoglu O, Kocakoc E, Kaya A, Kiris A (2006) Familial Mediterranean sfever responds well to infliximab: single case experience. Clin Rheumatol 25:83–87

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S. Erten.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Erten, S., Erten, S.F. & Altunoglu, A. Successful treatment with anti-tumor necrosis factor (anti-TNF)-alpha of proteinuria in a patient with familial mediterranean fever (FMF) resistant to colchicine: anti-TNF drugs and FMF. Rheumatol Int 32, 1095–1097 (2012). https://doi.org/10.1007/s00296-011-1855-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-011-1855-5

Keywords

Navigation